

FIGURE 1

		CDR1			CDR2			CDR3			
		10	20	30	40	50	52A	60	70	80	90
J20.8		GGSLKLSCHAASGFTFS	SYAMSWVRQTPAKRLEWVAYISRG	GGGIFYQQDSIKGRFTI							
F4.1		ET-----	-----	-----	-----	VST-----	S-TV-----				
F14.6		ALVKP-----	N-G-----	-----	E-----	-----	YS-----L-----V-----				
H9.3		ELVR--A-V-V-CTT--	NIKDDYIH-----	R-EQG-----	IGR-DPAN-KTK-APKFQDKA-----						
A2.1		GLVKP-A-V-V--NV--	YS-TG-F-N-----	SHG-S-----	GR-NPLN-DTF-NQKF-----	KA-----	KA-----L-----				

FIGURE 2

CDR2

YISRGGGIFYYQDSIKG
-----VST--S-TV--
A-----YS--L--V--

CDR3

EKYGKRG MDY (J20.8)
QKYNKRA MDY (F4.1)
TARATWDW FAY (F14.6)

FIGURE 3

Réponse anti-streptavidine




FIGURE 4A

Réponse anti-peroxydase




FIGURE 4B




FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8A




FIGURE 8B




FIGURE 9A

- pLK19
- CW-K19
- K19-P3
- PEI




FIGURE 9B


ACTIVITE ANTIVIRALE DES
ANTICORPS ANTI-ADN

FIGURE 10

FIGURE 11A


TITRES INFECTIEUX AU JOUR 13
Exp III

FIGURE 11B



Titres infectieux au jour 13
Exp V

FIGURE 11C






FIGURE 12




FIGURE 13A

FIGURE 13B




FIGURE 13D




FIGURE 13C